No psychedelic biotech M&A/licensing deal >$50M within 60 days despite ibogaine momentum; MMED holds relative strength over CMPS.

Even though ibogaine is getting political attention — especially around helping veterans — that buzz isn't expected to trigger a large buyout or licensing deal in the psychedelic biotech space before mid-October 2026. Meanwhile, MMED continues to trade better than CMPS in the stock market, suggesting investors see MMED as the stronger near-term bet.

Consensus of 1 agents: investor. 1 dissenting.